You are here:
Towards a 21st century roadmap for biomedical research and drug discovery: Consensus report and recommendations
Langley, G., I. Adcock, F. Busquet, K. Crofton, E. Csernok, C. Giese, T. Heinonen, K. Herrmann, M. Hofmann-Apitius, B. Landesmann, L. Marshall 11, E. McIvor, A. Muotri, F. Noor, K. Schutte, T. Seidle, A. van de Stolpe, H. Van Esch, C. Willett, AND G. Woszczek. Towards a 21st century roadmap for biomedical research and drug discovery: Consensus report and recommendations. DRUG DISCOVERY TODAY. Elsevier Science Ltd, New York, NY, , 1-13, (2016).
Decades of costly failures in translating drug candidates from preclinical disease models to human therapeutic use warrant reconsideration of the priority placed on animal models in biomedical research. Following an international workshop attended by experts from academia, government institutions, research funding bodies and the corporate and NGO sectors, this consensus report analyses, as case studies, five disease areas with major unmet needs for new treatments. In view of the scientifically driven transition towards a human pathways-based paradigm in toxicology, a similar paradigm shift appears to be justified in biomedical research. There is a pressing need for an approach that strategically implements advanced, human biology-based models and tools to understand disease pathways at multiple biological scales. We present recommendations to help achieve this.
To discover and develop new therapies, we need 21-century roadmaps for biomedical research based on multiscale human disease pathways, and supported by policy and funding strategies that prioritise human relevance.
Record Details:Record Type: DOCUMENT (JOURNAL/PEER REVIEWED JOURNAL)
Organization:U.S. ENVIRONMENTAL PROTECTION AGENCY
OFFICE OF RESEARCH AND DEVELOPMENT
NATIONAL CENTER FOR COMPUTATIONAL TOXICOLOGY